Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
10,370
Employees10,370
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
10,370
Employees10,370

ILMN Key Statistics

Market cap
22.98B
Market cap22.98B
Price-Earnings ratio
34.49
Price-Earnings ratio34.49
Dividend yield
Dividend yield
Average volume
1.92M
Average volume1.92M
High today
$155.31
High today$155.31
Low today
$148.17
Low today$148.17
Open price
$154.02
Open price$154.02
Volume
2.74M
Volume2.74M
52 Week high
$155.53
52 Week high$155.53
52 Week low
$68.70
52 Week low$68.70

Stock Snapshot

The current Illumina(ILMN) stock price is $150.00, with a market capitalization of 22.98B. The stock trades at a price-to-earnings (P/E) ratio of 34.49.

During the trading session on 2026-01-23, Illumina(ILMN) shares reached a daily high of $155.31 and a low of $148.17. At a current price of $150.00, the stock is +1.2% higher than the low and still -3.4% under the high.

Trading volume for Illumina(ILMN) stock has reached 2.74M, versus its average volume of 1.92M.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

ILMN News

Simply Wall St 1d
Why Illumina Is Up 5.9% After CMS Backs TruSight Oncology Comprehensive Reimbursement

Earlier in January 2026, Illumina announced that the Centers for Medicare and Medicaid Services granted reimbursement for its FDA-approved TruSight Oncology Com...

Why Illumina Is Up 5.9% After CMS Backs TruSight Oncology Comprehensive Reimbursement
TipRanks 3d
Illumina secures CMS reimbursement for TruSight in vitro cancer test

Illumina (ILMN) announced that reimbursement has been granted for its FDA-approved in vitro diagnostic TruSight Oncology, or TSO, Comprehensive test. TSO Compre...

TipRanks 3d
Illumina price target raised to $155 from $135 at Stifel

Stifel analyst Daniel Arias raised the firm’s price target on Illumina (ILMN) to $155 from $135 and keeps a Buy rating on the shares. The firm thinks there is “...

Analyst ratings

43%

of 23 ratings
Buy
39.1%
Hold
43.5%
Sell
17.4%

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.